A randomized phase 3 study found that first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared to osimertinib alone in patients with advanced non–small cell lung cancer (NSCLC) and concurrent EGFR and TP53 mutations. This study provides evidence for incorporating TP53-based molecular ris...
Inflammatory breast cancer is a rare and aggressive form of breast cancer with poor outcomes. Research highlights the role of ERβ as a mediator of estrogen signaling, demonstrating its tumor suppressive effects in preclinical models. ERβ's antimetastatic activity may hold promise for improving treatment options for IBC.
A recent study has identified specific miRNA signatures associated with EGFRI-induced skin rash, suggesting potential treatment-dependent biomarkers for this common side effect. The research found that miR-21 and miR-520e serum concentrations were negatively correlated with the severity of skin rash.
Researchers at Burnham Institute have discovered that gamma-secretase acts as a tumor suppressor by altering the EGFR pathway, which may limit treatment options for Alzheimer's and other diseases. The study also found that APP metabolite AICD negatively regulates transcription of the EGFR gene.
Researchers discovered that adding growth factor EGF to formula reduces NEC incidence by 50% compared to animals fed formula alone. This could be a preventative measure for NEC in human babies.